Skip to main content

What Insulet's Quarter ended Sep 30, 2026 10-Q says: 7 signals

Insulet filed its latest 10-Q with the SEC on Nov 4, 2026. It discusses capex increase, cloud investment and international growth.

Public (PODD)Medical Equipment Manufacturing10,000+ employeesinsulet.comLinkedIn

Get Insulet's live signals in Claude or ChatGPT, or by API

AskWhat changed at Insulet this week? Use Autobound signals for insulet.com.
Filed
Nov 4, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
23

Source: Autobound Signal API · 102 signals tracked for Insulet · updated

10-Q · latest 10

What Insulet's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 7 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 8 signals

    SEC EDGAR

Earlier 10-Q filings

  • 10-Q · Quarter ended Mar 31, 2026Filed · 8 signalsSEC EDGAR

Showing 10 of 23 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Insulet earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Revenue reached $842M up 19.2% with operating margin at 22%Third-quarter revenue reached $842 million, representing 19.2% reported growth and 19.6% constant currency growth. Gross margin reached 74.2% while adjusted operating margin expanded 490 basis points to 22.0%, showing strong operational leverage and budget flexibility.
Raised full year constant currency revenue growth outlook to 21%-22%Insulet narrowed its full-year revenue outlook to the high end of the prior range, anticipating 21% to 22% constant currency growth company-wide and 21.5% to 22.5% for total Omnipod. Adjusted operating margin expansion was lifted to approximately 150 basis points for full year 2026.
Expanded domestic sales force by nearly 25% in Q3Insulet executed its second US commercial sales force expansion in two years, increasing field capacity by nearly 25%. The expansion included a four-month certification program and additions of clinical retention specialists to the customer care team.
Full market release of Omnipod Discover completed in USInsulet launched Omnipod Discover across the US in October, scaling its proprietary engagement and decision-support platform. The release has already onboarded over 35,000 users and 5,000 clinicians to improve therapy retention and engagement.
Deployed first new commercial CRM platform in over a decadeInsulet rolled out a new CRM platform to its US sales team in August to modernize customer engagement, messaging, and account targeting. Ongoing optimization and field training initiatives are underway to leverage the new platform's capabilities across commercial workflows.
Global customer base grew over 20% past 600000 usersInsulet expanded its global active customer base by more than 20% year over year, building on the 600,000 baseline set at the end of last year. New customer starts grew low double digits year to date with more than 85% of starts converted from multiple daily injections.

Signal API · MCP

Track Insulet with the Signal API

One POST /v1/companies/enrich call with insulet.com returns Insulet 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"insulet.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Insulet 10-Q

When did Insulet file its latest 10-Q?
Insulet filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 4, 2026. The one before it was filed on Aug 5, 2026.
What did Insulet disclose in its latest 10-Q?
From the filing dated Nov 4, 2026: Insulet incurred $38.5M charge and expects $50M total cost from cannula manufacturing issues
What did Insulet say on its recent earnings calls?
Q3 FY2026: Revenue reached $842M up 19.2% with operating margin at 22% (dated Nov 4, 2026).
Where can I read Insulet's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1145197/000114519726000192/podd-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →